Notable regulatory approvals of emerging technologies over the past 30 days

Along with AI in its various iterations, the list may include virtual and augmented reality, 3D printing and visualization, robotics and other innovative technologies changing healthcare delivery.

Nanowear: FDA clearance for AI diagnostics and monitoring via wearable nanosensor platform (Sept. 28)

Wyss Center: CE mark certification for longitudinal, AI-preparatory brain visualization cloud software (Sept. 29)

Siemens: FDA clearance for photon-counting CT detectors. Hailed by the agency as “the first new major technological improvement for computed tomography imaging in nearly a decade” (Sept. 30)

IotaMotion: FDA de novo classification for robotic-assisted cochlear implant insertion system (Oct. 5)

Amber Implants: FDA breakthrough device designation for 3D-printed spinal implant system (Oct. 5)

SyncThink: FDA clearance for AI analysis of eye movement in mobile concussion diagnostics (Oct. 5)

DreaMed: Expanded FDA clearance for AI-guided insulin administration (Oct. 6)

Medtronic: CE mark certification for robotic-assisted surgery system (Oct. 11)

Delphinus: FDA premarket approval for 3D breast ultrasound tomography (Oct. 12)

Subtle Medical: Health Canada approval for AI enhancement of MRI and PET imaging (Oct. 13)

Cognetivity Neurosciences: FDA approval for AI-aided rapid dementia assessment (Oct. 20)

Panakeia: CE mark certification for AI breast cancer image analysis (Oct. 21)

Naviswiss: FDA clearance for digital hip replacement surgery planning (Oct. 21)

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”